Symptom management after initial prostate cancer treatment

A recently published study has provided us with interesting information on how patients can be taught to better “self-manage” post-treatment, problematic symptoms associated with first-line treatment of localized prostate cancer. … READ MORE …

“If all you have is a hammer, everything looks like a nail”

It was called “instrument bias” by Abraham Maslow and Abraham Kaplan, but for present purposes, we’ll call it “specialty bias” — over-reliance on the tool one is most familiar with. … READ MORE …

Full results of apalutamide in treatment of mHSPC

At the end of January, we had reported that the results of the TITAN trial — the Phase III trial of standard ADT + apalutamide (Erlead) or standard ADT + a placebo in men with metastatic, hormone-sensitive prostate cancer (mHSPC) — were positive, and that they were going to be reported at a meeting later in the year. … READ MORE …

Is whole pelvic radiation needed for primary treatment of Gleason 9/10 prostate cancer?

Whether whole pelvic radiation therapy (WPRT) is beneficial for men newly diagnosed with Gleason grade 9/10 (Grade Group 5) is controversial. … READ MORE …

UPDATE … the new PCa Social Network PLUS app

A couple of weeks ago (see here) we had first told you about the launch of the new PCa Social Network PLUS app that allows mobile access to a new social netowrk (and a clinical trial of its effects) for men with prostate cancer. … READ MORE …

PD-1 and PD-L1 checkpoint inhibition in treatment of prostate cancer

We have noted several times in the past that, at least to date, compared to the results shown by the PD-1 and PD-L1 checkpoint inhibitors in the treatment of cancers like lung cancer, kidney cancer, and melanoma, there has been little evidence of the value of these agents in the treatment of advanced prostate cancer. … READ MORE …

The upcoming APCCC 2019 meeting on advanced prostate cancer

The first iteration of the Advanced Prostate Cancer Consensus Conference (APCCC) was held in St. Gallen, Switzerland, in 2017, and the second iteration is upcoming in late August this year — this time in Basel. … READ MORE …